| Metric | Current Period | Prior Year Period | YoY |
|---|---|---|---|
| Revenue / Net Sales | ¥23788.2B | ¥27773.7B | -14.3% |
| Operating Income | ¥1050.4B | ¥650.8B | +61.4% |
| Ordinary Income | ¥1007.4B | ¥532.8B | +89.1% |
| Net Income | ¥608.5B | ¥509.8B | +19.4% |
| ROE | 1.6% | 1.4% | - |
For FY2027 (ending Feb 2027) Q1 results, Revenue was ¥23,788B (YoY ▲¥3,985B ▲14.3%), i.e., a decline, but Operating Income rose to ¥1,050B (YoY +¥400B +61.4%), Ordinary Income to ¥1,007B (YoY +¥475B +89.1%), and Net Income to ¥606B (YoY +¥116B +19.4%), representing substantial profit growth. The revenue decline was mainly due to segment reorganization causing deconsolidation of Other Businesses; Domestic CVS grew +3.1% and Overseas CVS +2.0% on a like-for-like basis. Operating margin improved to 4.4% from 2.3% a year ago (+2.1pt), gross margin 15.6% (+0.7pt), and SG&A ratio 26.1% (▲1.0pt), reflecting cost efficiencies. Overseas CVS Operating Income surged to ¥656B (YoY +655.1%), more than 7.5x, driving group-level profit growth. However, recognition of Special Losses of ¥195B (including impairment of ¥98B) limited the conversion from Ordinary Income to Net Income, resulting in a conversion ratio of 60.3%. Operating Cash Flow was very strong at ¥3,435B, 5.6x Net Income, and Free Cash Flow was ¥2,710B, confirming ample cash generation.
[Revenue] Revenue was ¥23,788B (YoY ▲14.3%), a large decline driven by structural factors. Due to segment reorganization, Superstore Business and Specialty Store Business (Pia, Tower Records, etc.) were transferred from Other Businesses to Domestic CVS, shrinking remaining Other Business sales to ¥131B (prior ¥4,609B) and producing a headline decline. On a like-for-like basis, Domestic CVS Revenue was ¥2,299B (+3.1%) and Overseas CVS Revenue was ¥21,358B (+2.0%), maintaining positive growth. Domestic CVS delivered comps +2.0%, customer traffic +1.5%, and average ticket +0.5%, with freshly made Seven Cafe counter items increasing daily sales by +14.7%. Overseas CVS comps were +1.4%, with merchandise sales +0.6% and gasoline sales +3.2% growth; however, same-store unit volumes fell ▲8.8%, so revenue growth was driven by price/mix improvements.
[Profitability] Operating Income of ¥1,050B (+61.4%) was supported by both gross margin improvement and cost rationalization. Gross profit margin improved to 15.6% (prior 15.0%, +0.7pt); Domestic CVS merchandise gross margin was 32.0% (+0.3pt) and Overseas CVS merchandise gross margin was 33.2% (flat), supporting margin improvement. SG&A was ¥6,199B (SG&A ratio 26.1%, ▲1.0pt YoY), with headcount optimization and system reorganization effects materializing. By segment, Overseas CVS Operating Income jumped to ¥656B (prior ¥87B), more than 7.5x, driven by North Star plan initiatives: 43 franchise conversions, 72 gasoline wholesale conversions, and closure of 45 unprofitable stores, materially improving profitability. Domestic CVS Operating Income was ¥522B (▲4.2%) — a slight decline — but maintained a high margin of 22.7%; higher system and advertising costs (+¥88B) were the profit-reduction factors. Ordinary Income was ¥1,007B (+89.1%), with equity-method income of ¥34B contributing positively while interest expense of ¥60B was largely absorbed by operating profit gains. The pre-tax profit of ¥852B converted to Net Income of ¥606B at a conversion rate of 71.2%, after income taxes of ¥243B (effective tax rate 28.6%). Special Losses of ¥195B (impairment ¥98B, disposal losses ¥41B, etc.) widened the gap between Ordinary Income and Net Income; these were one-time items related to store closures and restructuring. In conclusion, the shift to a structure of lower revenue but higher profitability has become clear.
The core business is Overseas Convenience Stores, with Revenue ¥21,358B (90.3% of total) and Operating Income ¥656B (50.4% of total), the largest scale segment. Operating Income increased YoY +655.1% (more than 7.5x), the main driver of corporate-level profit growth. Margin improved to 3.1% from 0.4% (+2.7pt), directly reflecting North Star plan measures: 43 franchise conversions, 72 gasoline wholesale conversions, and 45 unprofitable store closures. Gasoline CPG (gross profit per gallon) improved by +16.2 cents, and SG&A reductions also contributed. Domestic CVS Revenue was ¥2,299B (9.7% of total) with Operating Income ¥522B (40.1% of total), maintaining a high margin of 22.7% but recording a slight YoY decline of ▲4.2%. Same-store sales growth of +2.0% continued, but higher system and advertising costs (+¥88B) reduced profits. Other Businesses were substantially downsized by the reorganization, with Revenue ¥131B and Operating Income ¥15B. There is a notable profit margin gap between segments: Domestic CVS 22.7% vs Overseas CVS 3.1% (~7x difference), so leveraging scale in overseas operations to further improve profitability is a future focus.
Profitability metrics show ROE 1.6% (prior approx. 1.8%) at a low level, but Net Profit Margin improved to 2.5% (prior 1.8%, +0.7pt). Operating margin improved to 4.4% (prior 2.3%, +2.1pt), gross margin 15.6% (+0.7pt), and SG&A ratio 26.1% (▲1.0pt), indicating an improved cost structure. Total asset turnover declined to 0.249x (prior 0.304x), with revenue contraction and total assets increasing (¥9.14T → ¥9.57T) reducing efficiency. Estimated ROIC is 1.8%, signaling low capital efficiency; large goodwill of ¥2.12T and intangible assets ¥2.48T depress asset turnover. Cash quality is excellent: Operating Cash Flow / Net Income = 5.65x, showing strong cash backing for profits. With OCF of ¥3,435B and FCF of ¥2,710B, after Capex of ¥742B the company still generates abundant cash. Capex / Depreciation = 0.80x, indicating maintenance-oriented investment levels. Financial soundness shows Equity Ratio 38.9% (prior 39.6%) stable, but Current Ratio 94.0% (prior 78.5%) is below 100% and short-term liquidity requires monitoring. Cash and deposits ¥6,615B broadly cover short-term debt, but reliance on operating liabilities such as Accounts Payable ¥5,273B and Deposits ¥3,288B is high. Debt/EBITDA is 5.14x, indicating moderate to high leverage relative to earnings; goodwill / equity 57.1% and goodwill / EBITDA 10.7x show structural risk associated with intangible asset burden.
Operating Cash Flow ¥3,435B (YoY +46.0%) demonstrates very strong cash generation at 5.65x Net Income ¥606B. A subtotal of ¥3,758B was enhanced by working capital changes: increases in Accounts Payable +¥1,046B and Deposits +¥1,508B boosted OCF. Inventory increase ▲¥156B and trade receivables increase ▲¥391B are considered seasonal fluctuations. Corporate tax payments ▲¥222B were at normal levels. Investing Cash Flow was ▲¥725B, mainly due to Capex ▲¥742B; purchases of investment securities ▲¥13B and sales +¥22B resulted in net cash inflow, and proceeds from subsidiary sales +¥132B indicate cash conversion from restructuring. Financing Cash Flow was ▲¥535B: although long-term borrowings +¥3,242B were raised significantly, short-term borrowings repayments ▲¥765B, bond redemptions ▲¥1,962B, and long-term borrowings repayments ▲¥431B led to net repayment of ▲¥156B. Dividend payments ▲¥573B were high for a quarter but were comfortably covered by FCF ¥2,710B. Cash generation assessment is strong: OCF/EBITDA 1.74x and FCF ¥2,710B secure capacity for growth investment and additional debt repayment. However, the OCF boost from increased Accounts Payable and Deposits is seasonal/timing-driven, so potential reversal in subsequent quarters warrants attention.
Ordinary Income ¥1,007B vs Net Income ¥606B yields a conversion ratio of 60.3%, a sizable gap primarily due to one-time items. Special Losses ¥195B (impairment ¥98B, disposal losses ¥41B, etc.) compressed Net Income; last year included gain on sale of fixed assets ¥372B, so YoY special item impact was ▲¥567B. Non-operating income ¥77B (0.3% of Revenue) is small and not a structural dependency. Non-operating expenses ¥120B are mainly interest expense ¥60B, within normal financing cost range. Equity-method income ¥34B is a stable earnings source. Accrual ratio is ▲3.0%, healthy, and OCF ¥3,435B substantially exceeds Net Income ¥606B, indicating strong cash backing for profits. Under JGAAP, goodwill amortization ¥358B (18.1% of EBITDA) is an accounting-specific profit-reducing factor; therefore EBITDA-based comparisons with IFRS peers are appropriate. The quality of recurring earnings is solid, and operating improvements form a foundation for sustainable profit growth.
Full Year guidance: Operating Income ¥4,250B (YoY +0.5%), Ordinary Income ¥3,900B (YoY +3.3%), Net Income ¥2,780B, EPS ¥120.89, Dividend ¥30. The interim figures were revised up: Operating Income to ¥2,340B (+¥440B) and Net Income to ¥1,350B (+¥300B). Q1 progress rates are Revenue 22.8% (standard 25%: ▲2.2pt), Operating Income 24.7% (standard ▲0.3pt), Net Income 21.8% (standard ▲3.2pt); operating progression is near standard but Net Income is slightly lagging. The lag is attributable to Q1 one-time Special Losses of ¥195B and is judged recoverable in H2. Overseas CVS profitability exceeded assumptions and, under the revised interim assumptions, merchandise gross margin is assumed 33.7% (H2 34.0%) with same-store sales +0.5% (H2 +2.1%), expecting further earnings acceleration into H2. FX assumption was changed to USD/JPY ¥157.00 (previous ¥150), a yen depreciation that boosts yen-converted overseas CVS earnings. Order backlog data were not disclosed, but North Star plan execution (200 unprofitable store closures, 390 F/C conversions, 350 gasoline wholesale conversions) is progressing toward the full-year and supports improvement potential in H2. No metric differs from plan by more than ±10%, so plan achievability is judged high.
Dividend is ¥30 per share (prior ¥25, +¥5 +20%), implying a payout ratio of about 24.8% versus full-year EPS forecast ¥120.89, a healthy level. Q1 dividend payout ¥573B vs quarterly Net Income ¥606B implies a payout ratio of ~95% for the quarter, but this is due to front-loaded payment timing and is comfortably covered by FCF ¥2,710B. Cash & deposits ¥6,615B (prior ¥4,386B) are ample, and dividend payment capacity is not problematic. Share buybacks are not indicated for this term; capital allocation is dividend-focused. Total Return Ratio is approximately 24.8% via dividends only, balancing shareholder returns while preserving growth investment capacity. The +20% dividend increase from ¥25 to ¥30 marks the third consecutive year of dividend increases, confirming a strengthening shareholder-return stance.
[Short-term] Acceleration of Overseas CVS North Star plan measures (planned H2 closures of 155 unprofitable stores, 347 F/C conversions, and 278 gasoline wholesale conversions) will support profitability improvement. In Domestic CVS, completion of expansion to 18,000 Seven Cafe Bakery stores and 10,000 Tea stores, plus launch of 7NOW mobile ordering, will boost same-store sales. Store refurbishments for 200 Overseas CVS stores starting in H2 are expected to drive merchandise gross margin toward 34.0%, an upside factor. Interim results (scheduled November) will be a key event to confirm progress.
[Long-term] Introduction of a new contract type for Domestic CVS toward FY2030 aims for net store addition of 1,000 stores, supporting network strengthening and market share expansion. Establishment of a retail media subsidiary targets ¥20B in revenue by FY2030, creating a new revenue stream and growth driver. Strengthening Overseas CVS product assortments (annual 220 PB new items, 50 restaurant openings) and same-store improvements are expected to establish long-term competitive advantage. Full-scale ROIC management adoption to improve capital efficiency, plus DX, system, and security investments to strengthen the management base, are expected to drive enterprise value improvement.
Profitability & Returns
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Operating Margin | 4.4% | 3.4% (0.8%–7.7%) | +1.0pt |
| Net Margin | 2.6% | 2.2% (0.5%–6.2%) | +0.3pt |
Both Operating Margin and Net Margin exceed industry medians, indicating profitability above industry average.
Growth & Capital Efficiency
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Revenue Growth (YoY) | -14.3% | 7.7% (0.8%–14.6%) | -22.0pt |
Revenue growth rate is well below the industry median, but this is mainly due to structural effects from segment reorganization; on a like-for-like basis both Domestic and Overseas CVS maintain growth.
※Source: Company compilation based on public financial statements
Short-term liquidity risk: Current Ratio 94.0% and Quick Ratio 81.5% are below 100%; current liabilities ¥1.95T vs current assets ¥1.83T produce a shortfall of ¥116.4B. Cash & deposits ¥6,615B generally cover short-term borrowings ¥593B, current bonds ¥600B, current portions of long-term borrowings ¥2,450B, and current lease obligations ¥1,677B, but high reliance on operating liabilities such as Accounts Payable ¥5,273B and Deposits ¥3,288B means settlement timing mismatches could affect liquidity.
Structural goodwill risk: Goodwill ¥2.12T equals 57.1% of equity ¥3.69T and 10.7x EBITDA ¥1,976B, indicating inherent impairment risk. Goodwill amortization ¥358B represents 18.1% of EBITDA and is a JGAAP-specific profit-compressing factor. Impairment loss of ¥98B was recognized this term; if Overseas CVS operating environment deteriorates or profitability weakens, additional impairments could materially compress Net Income. Debt/EBITDA 5.14x implies relatively high leverage versus earnings, and EBITDA deterioration could rapidly impair financial health.
Concentration and external-environment risk in overseas operations: Overseas CVS accounts for 90.3% of Revenue, creating portfolio concentration. North American CVS faces wage inflation (minimum wage increases), fuel price and input cost volatility, and Q1 showed gasoline volume decline at existing stores of ▲8.8%, signaling reduced customer visit frequency. FX (USD/JPY) volatility can significantly swing Revenue, Profit, and Equity; yen depreciation versus the ¥157 full-year assumption is upside, while yen appreciation is a downside. Regulatory changes (tobacco, alcohol sales, etc.) could also impact profitability.
Sustainability of margin improvement trend: Operating Margin improved from 2.3% to 4.4% (+2.1pt) as Overseas CVS North Star plan measures (closures of unprofitable stores, F/C conversions, gasoline wholesale conversions) transform the profit structure. Merchandise gross margins remain high at Domestic 32.0% and Overseas 33.2%, and SG&A ratio declined to 26.1% (▲1.0pt). The plan targets Overseas CVS merchandise gross margin of 34.0% and 200 store refurbishments in H2, suggesting continued margin uplift is likely. Key items to monitor are sustainability of Domestic CVS KPIs (customer traffic +1.5%, average ticket +0.5%) and post-refurbishment comp sales acceleration in Overseas CVS (H2 target +2.1%).
Balance between cash generation and capital allocation: OCF ¥3,435B (OCF/Net Income 5.65x) and FCF ¥2,710B confirm very strong cash generation, funding Capex ¥742B and dividends ¥573B. Capex/Depreciation 0.80x is maintenance-centric, but there is room to accelerate growth investments toward FY2030 (net +1,000 new contract-type stores, ¥20B retail media revenue). With payout ratio 24.8% and cash & deposits ¥6,615B, liquidity for returns is ample. Key risks are reversal of working capital boosts (Accounts Payable/Deposits) and reduction of Debt/EBITDA 5.14x — both will influence cash allocation prudence.
Need to improve total asset turnover and ROIC: Total asset turnover declined to 0.249x (prior 0.304x), and estimated ROIC remains low at 1.8%. Large goodwill ¥2.12T and intangible assets ¥2.48T suppress asset efficiency; improving capital efficiency requires both EBITDA growth and asset reduction. Full implementation of ROIC management was disclosed; progress on specific measures (portfolio review, disposal of idle assets, strengthening investment decision discipline versus cost of capital) will be key to re-rating valuation.
This report is an automated earnings analysis document generated by AI integrating XBRL earnings release data and PDF presentation materials. It is not a recommendation to invest in any particular security. Industry benchmarks are reference information compiled by the company from public financial statements. Investment decisions are your responsibility; consult a professional advisor as needed.